KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($1.12), $0.16 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $1.43 million versus the consensus estimate of $951.67 thousand.

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.